Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (101-110 of 157) with videos related to

Pageof 16
Sort By:
Breast Cancer (Tokyo, Japan)|June 13, 2024
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusMelinda L Telli, Jennifer K Litton, J Thaddeus Beck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.
Cancer Research|August 1, 2022
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast CancerChengyue Wu, Angela M Jarrett, Zijian Zhou, et al.
The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.
NPJ Breast Cancer|December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activityJ K Litton, M Scoggins, D L Ramirez, et al.
Breast Cancer Research and Treatment|June 12, 2016
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancerBanu K Arun, Yun Gong, Diane Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialJ K Litton, S A Hurvitz, L A Mina, et al.
JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 28, 2021
Effector memory cytotoxic CD3<sup>+</sup>/CD8<sup>+</sup>/CD45RO<sup>+</sup> T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancerXiangjie Sun, Jie Zhai, Baohua Sun, et al.
Pageof 16

Showing results (101-110 of 157) with videos related to

Sort By:
Pageof 16
Breast Cancer (Tokyo, Japan)|June 13, 2024
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusMelinda L Telli, Jennifer K Litton, J Thaddeus Beck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.
Cancer Research|August 1, 2022
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast CancerChengyue Wu, Angela M Jarrett, Zijian Zhou, et al.
The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.
NPJ Breast Cancer|December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activityJ K Litton, M Scoggins, D L Ramirez, et al.
Breast Cancer Research and Treatment|June 12, 2016
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancerBanu K Arun, Yun Gong, Diane Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialJ K Litton, S A Hurvitz, L A Mina, et al.
JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 28, 2021
Effector memory cytotoxic CD3<sup>+</sup>/CD8<sup>+</sup>/CD45RO<sup>+</sup> T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancerXiangjie Sun, Jie Zhai, Baohua Sun, et al.
Pageof 16